Please assess the completion status of the following clinical trial:

Trial Title: Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute-care inpatients;~* Aged 18 years or older;~* At least one dose of echinocandin therapy during the hospitalization;~* Primary or secondary ICD-9 discharge diagnosis of invasive candidiasis / candidemia.~Exclusion Criteria:~* \< 18 years of age;~* No recorded echinocandin therapy during hospitalization;~* Acetaminophen hepatotoxicity;~* Pre-existing autoimmune hepatitis;~* Autoimmune/metabolic liver disease;~* Primary biliary cirrhosis;~* Primary sclerosing cholangitis and orthotopic liver transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Cases (Type: None): Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
- Controls (Type: None): Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)

Based on this trial design, predict the completion outcome and termination type (if applicable).